Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Intermittent or Continuous Panitumumab Plus FOLFIRI for First-line Treatment of Patients With RAS/B-RAF Wild-type Metastatic Colorectal Cancer: a Randomized Phase 2 Trial

NCT04425239 is registered in ClinicalTrials.gov with National Cancer Institute, Naples as lead sponsor.

NCT NCT04425239
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04425239 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Intermittent or Continuous Panitumumab Plus FOLFIRI for First-line Treatment of Patients With RAS/B-RAF Wild-type Metastatic Colorectal Cancer: a Randomized Phase 2 Trial
Lead sponsor
National Cancer Institute, Naples
Phase
Phase 2
Overall status
Completed
Start date
May 21, 2018
Completion date
April 3, 2022
Enrollment
151 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer stage iv